Ruth Khalili Friedman

Graduada em medicina (1992), residência médica em Doenças Infecciosas e Parasitárias (1995) e Doutora em Ciências da Saúde, Epidemiologia Geral (2006). No Instituto Nacional de Infectologia Evandro Chagas INI, Fiocruz, atua na assistência médica e na pesquisa clínica e epidemiológica em Doenças Infecciosas e Parasitárias (1995) e é docente do curso de pós-graduação stricto sensu em Pesquisa Clínica em Doenças Infecciosas (2008). Em 2021-2023, realizou capacitação em PD&I pelo programa INOVA LABS Fiocruz e pelo Catalisa ICT/Sebrae.

Graduated in Medicine at the Fundação Técnico Educacional Souza Marques (1992), medical residency in Infectious and Parasitic Diseases at the Pedro Ernesto University Hospital (1995) and doctorate in General Epidemiology and Public Health at the National School of Public Health (2006). From 1995 to 2002, she worked on HIV seroincidence study in men who have sex with men, on the study of post-sexual prophylaxis against HIV and on the HIV vaccine study by the Federal University of Rio de Janeiro. Since 1995, she has been working as an infectious disease physician, epidemiologist and researcher at the Evandro Chagas Clinical Research Institute / FIOCRUZ, where she is a member of the postgraduate teaching staff since 2008. She has extensive experience in the area of ​​prevention and treatment of sexually transmitted infections, HIV / AIDS and its comorbidities, HIV / HPV co-infection, syphilis, and expertise in clinical and epidemiological research. From 1996 to 2016, she worked in the INI / FIOCRUZ cohort of women with HIV / AIDS with a focus on HIV / HPV coinfection, reproductive choices, contraception and menopause. From 2009 to 2016, she worked in the INI / FIOCRUZ cohort of men with and at high risk for HIV / AIDS with a focus on HIV / HPV coinfection and other STIs. Since 2016, she has been working in the INI / FIOCRUZ cohort of transsexual women with and at high risk for HIV / AIDS, with a focus on hormone therapy and antiretrovirals ontercations, STIs, HIV seroincidence, behavioral aspects, violence, among others. She also have been working with research and gynecological assistance aimed at transsexual women who underwent surgical procedures for the adequacy of sex, focusing on studies of neovaginal and anal microbiome, STIs HPV, Chlamydia trachomatis, Neisseria gonorrhoeae, and syphilis. She worked in HIV Prevention Trials Network studies, such as the HPTN 052 study as co-investigator and HPTN 063 as the principal investigator. In the study AACTG 5316 (Evaluating Pharmacokinetic Interactions with Vaginal Ring Contraceptives and Antiretroviral Therapy) she served as principal investigator and co-investigator in the AACTG 5298 (A Phase 3 Trial of the Quadrivalent HPV Vaccine in Older HIV + Adults) studies, in HPV-019 PRI (A Phase 4 Trial to evaluate safety and immunogenicity of CervarixTM from GSK Biologicals vs. Gardasil® from Merck in HIV-infected women with 15 to 25 years old), and in The Opposite Attract Study, from the Kirby Institute, Australia, which evaluated the impact of antiretroviral treatment on HIV seroincidence among HIV serodiscondant couples of men who have sex with men.